New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 12, 2014
09:25 EDTPRGO, IPXLPerrigo announces FDA approval of generic version of Astepro nasal spray
Perrigo (PRGO) announced that it has received final approval from the FDA on its Abbreviated New Drug Application for azelastine hydrochloride nasal spray. The ANDA involved contributions from both Perrigo and Impax Laboratories (IPXL), who will share certain costs and benefits of this product. Perrigo and Impax continue to be in first to file Hatch Waxman patent litigation with Meda Pharmaceuticals in the United States District Court for the District of New Jersey. Perrigo has commenced shipment of product to its customers. Annual sales were approximately $97M annually, as measured by Symphony Health Solutions.
News For PRGO;IPXL From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 21, 2015
07:37 EDTPRGOPfizer replaces AbbVie as top global pharma pick at Jefferies
Subscribe for More Information
May 19, 2015
06:08 EDTPRGOPerrigo CEO says would talk with Mylan, but at a higher price, Globes reports
Subscribe for More Information
May 18, 2015
12:07 EDTPRGOPerrigo: there is price point where would engage with Mylan, Bloomberg reports
Subscribe for More Information
May 12, 2015
08:48 EDTPRGOPerrigo acquires Patheon's Mexican operations for $34M
Subscribe for More Information
May 11, 2015
19:15 EDTIPXLOn The Fly: After Hours Movers
Subscribe for More Information
16:43 EDTIPXLImpax performs GMP, pre-approval inspections of Impax Hayward facility
Subscribe for More Information
16:15 EDTIPXLImpax says FDA issued Form 483 after facility inspection
Subscribe for More Information
16:14 EDTIPXLImpax reaffirms outlook for 2015
Impax still sees 2015 adjusted gross margins as a percent of total revenue are expected to be in the mid 50% range, adjusted total research and development expenses across the generic and brand divisions of $80M-$85M and capital expenditures of $45M-$50M.
16:13 EDTIPXLImpax reports Q1 adjusted EPS 9c, consensus 18c
Reports Q1 revenue $143.1M, consensus $146.13M. The company said, "This quarter's revenues were negatively impacted by the later than anticipated close of the Tower acquisition, the delayed launch of lamotrigine ODT, which was launched in April due to delayed receipt of inventory from our supplier, and the deferred recognition of product sales from the launch of RYTARY. In addition, product sales mix in the combined portfolio as well as costs related to successfully launching RYTARY and the financing of the Tower acquisition led to a reduction in our first quarter earnings."
15:00 EDTIPXLNotable companies reporting after market close
Subscribe for More Information
11:53 EDTPRGOTeva rejected chance to acquire Perrigo a few months ago, Globes reports
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use